A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or Metastatic Cancer
This research study is testing a new way to treat certain advanced cancers that have spread in the body. It involves a new drug called RO7759065, used alongside an established cancer treatment called atezolizumab. This is an early-stage study, meaning it's one of the first times these drugs are being given to people. The main goals are to make sure the combination is safe for patients and to see if it shows promise in treating different types of solid tumours. The study is open to adults aged 18 and over, and both men and women can take part. If you or someone you know has advanced cancer, this study might be an option, but it's important to discuss it thoroughly with your doctor.
At a glance
What is this study about?
This study is an important step in trying to find better ways to treat cancer. It's looking at a new medicine, RO7759065, that hasn't been widely used in people before, and combining it with a drug called atezolizumab, which is already used to treat some cancers. The idea is that these two drugs might work better together than either one alone.
This kind of research is called a 'Phase 1' study. This simply means it's an early stage where doctors are mainly checking if the new treatment combination is safe for people to take. They also start to look at how the body handles the drugs and if there are any signs that it could help treat the cancer.
The cancers this study is focusing on are ones that are 'locally advanced' (meaning they have grown quite a bit in one area) or 'metastatic' (meaning they have spread to other parts of the body). These are often harder to treat, so researchers are always looking for new and more effective options. This study aims to gather important information that could lead to new treatments for these types of cancer in the future.
Key takeaways
- This study tests a new drug combination for advanced solid cancers.
- It's an early-stage study focusing on safety and initial effectiveness.
- Open to adults aged 18 and over with specific types of advanced cancer.
- Participation involves regular clinic visits, treatments, and health checks.
- Potential benefits include access to new treatment, but risks and side effects are possible.
- You can withdraw from the study at any time without penalty.
Who may be eligible?
This study is open to adult patients who are 18 years old or older. Both men and women are welcome to take part.
To be considered for this study, you must have been diagnosed with a solid tumour. This means a cancer that forms a lump or mass, rather than a blood cancer. This cancer should also be 'locally advanced,' meaning it has grown significantly in its original area, or 'metastatic,' which means it has spread to other parts of your body.
There will be other, more detailed requirements that the study doctors will check to make sure the treatment is safe and suitable for you. These might include things like your general health, past treatments, and specific test results. Your doctor will discuss all of these with you carefully.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of a solid tumour (not a blood cancer)?
- Has your cancer been described as 'locally advanced' or 'metastatic' (spread to other parts of the body)?
- Are you able to attend regular clinic appointments for treatment and check-ups?
What does participation involve?
If you decide to join this study, you will be given the new study drugs, RO7759065 and atezolizumab, according to a schedule set by the study doctors. This will involve regular visits to the clinic for treatments and check-ups. During these visits, you'll have various medical tests, such as blood tests, scans (like CT scans), and physical examinations, to monitor your health and see how your cancer is responding.
The exact number of visits, tests, and the total length of time you'll be involved in the study can vary. It will depend on how your body reacts to the treatment and the specific plan for your care. You will have regular contact with the study team, and they will be there to support you and answer your questions throughout your participation. After your treatment period, there will also be follow-up appointments to continue monitoring your health over time.
Potential risks and benefits
Locations (3)
- —UnverifiedItaly
- —UnverifiedSpain
- —UnverifiedFrance
Common questions
What kind of cancer is this study for?
It's for adults with solid tumours (cancers that form a lump) that are locally advanced or have spread to other parts of the body.
What does 'Phase 1' mean?
It's an early stage of testing where doctors check if the new drug combination is safe and if it shows any signs of working.
Will I get a new medicine or a standard treatment?
You will receive a new medicine, RO7759065, combined with an existing cancer drug, atezolizumab, as part of the study.
Can I leave the study if I change my mind?
Yes, you have the right to leave the study at any time, and it won't affect your medical care.
What are the main goals of this study?
The main goals are to check the safety of the new drug combination and see how well it works against advanced cancers.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.